Your Patients Can't Find Bijuva — Here's How You Can Help

If your patients are coming back to your office frustrated because they can't fill their Bijuva prescription, you're not alone. Providers across the country are hearing the same story: the pharmacy doesn't carry it, it's on backorder, or the cost is prohibitive.

Bijuva (Estradiol and Progesterone capsules) is the only FDA-approved combination of bioidentical estradiol and bioidentical progesterone, making it a preferred choice for many menopausal patients. But its brand-only status, single-source manufacturing by Mayne Pharma, and inconsistent retail pharmacy stocking create real barriers to patient access.

This guide provides actionable steps your practice can take to help patients get their Bijuva — or a suitable alternative — without unnecessary delays.

Current Availability Landscape

Before diving into solutions, here's what the supply picture looks like in 2026:

• Not a formal shortage: Bijuva is not on the FDA drug shortage list
• Wholesale supply is adequate: The drug is generally available through major distributors
• Retail stocking is the bottleneck: Many chain pharmacies don't routinely carry it due to low local demand and high inventory cost ($257–$351 per 30-day supply)
• No generic exists: 24 active patents; no approved ANDA
• Specialty and independent pharmacies are more likely to stock or order it

For a detailed timeline and analysis, see our provider briefing on the Bijuva shortage situation in 2026.

Why Patients Can't Find Bijuva

Understanding the root causes helps you counsel patients more effectively:

Pharmacy Inventory Economics

Retail pharmacies make stocking decisions based on turnover. A brand-name-only product that costs $250+ wholesale and may only be dispensed a few times per month at a given location doesn't justify the shelf space from a pharmacy operations perspective. This is especially true at high-volume chain pharmacies.

Insurance and PBM Barriers

Many plans require prior authorization for Bijuva, and some mandate step therapy — requiring patients to try (and fail) a cheaper combination HRT before approving Bijuva. This adds delays and can discourage both patients and pharmacy staff.

Patient Awareness Gaps

Many patients don't know they can ask their pharmacy to special-order medication, try a different pharmacy, or use tools like Medfinder to search for availability. They hear "we don't have it" and assume it's unavailable everywhere.

What Providers Can Do: 5 Steps

Step 1: Set Expectations at Prescribing

When you write a Bijuva prescription, prepare your patient for the possibility that their pharmacy may not have it in stock. A brief heads-up — "This is a specialty medication, so your pharmacy might need to order it. If they don't carry it, here's what to do" — can prevent frustration and therapy interruptions.

Consider providing patients with a printed handout that includes:

• The Medfinder website (medfinder.com) for pharmacy searching
• The Bijuva copay savings card information (bijuva.com/savings.php)
• Alternative pharmacies in your area known to carry Bijuva

Step 2: Direct Patients to Medfinder

Medfinder allows patients (and your staff) to search for pharmacies with Bijuva in stock by zip code. This eliminates the guesswork and phone calls that delay prescription fills.

You can also share our patient-facing guide: How to Find Bijuva in Stock Near You.

Step 3: Build Pharmacy Relationships

Identify 2-3 pharmacies in your practice area that reliably stock or can quickly order Bijuva. Good candidates include:

• Independent pharmacies with a women's health focus
• Specialty pharmacies serving hormone therapy patients
• Mail-order pharmacies affiliated with major PBMs

Once you have reliable pharmacy partners, you can route Bijuva prescriptions there directly, bypassing the chain pharmacy availability problem entirely.

Step 4: Assist With Insurance Navigation

Prior authorization and step therapy requirements are common barriers. Your practice can streamline this by:

• Submitting prior authorization proactively when prescribing Bijuva
• Documenting why bioidentical combination therapy is clinically appropriate (e.g., patient preference for FDA-approved bioidentical vs. compounded, intolerance to synthetic progestogens)
• Having appeal letter templates ready for initial denials
• Directing patients to the Bijuva copay card ($35/month with commercial insurance, $75/month cash)

Step 5: Have a Backup Plan Ready

When Bijuva truly cannot be obtained in a reasonable timeframe, have alternative treatment plans prepared. The most clinically similar alternatives include:

1. Separate Estradiol + Progesterone: Generic oral Estradiol (0.5–1 mg) plus generic micronized Progesterone (100 mg) — same bioidentical hormones, $25–$70/month combined
2. Activella (generic available): Estradiol/Norethindrone — $20–$60/month
3. Prempro (generic available): Conjugated estrogens/Medroxyprogesterone — $15–$50/month

Alternatives: A Quick Comparison for Prescribers

When discussing alternatives with patients, this comparison may be helpful:

• Bijuva: Bioidentical E2 + bioidentical P4 — one capsule — brand only — $257–$351/month
• Estradiol + Prometrium (separate): Bioidentical E2 + bioidentical P4 — two pills — generic — $25–$70/month
• Activella: Bioidentical E2 + synthetic progestogen — one tablet — generic — $20–$60/month
• Prempro: Conjugated estrogens + synthetic progestogen — one tablet — generic — $15–$50/month

For a patient-facing version, share our guide on alternatives to Bijuva.

Workflow Tips for Your Practice

Here are some practical workflow recommendations:

• Flag Bijuva in your EHR: Add a prescribing alert or note that reminds staff to verify pharmacy availability before sending the prescription
• Create a patient resource sheet: Include Medfinder, the copay card link, and recommended pharmacies
• Track prior auth outcomes: Know which insurers consistently approve or deny Bijuva so you can counsel patients appropriately
• Consider e-prescribing to specific pharmacies: Route Bijuva prescriptions to pharmacies you've confirmed carry it, rather than defaulting to the patient's usual chain pharmacy
• Schedule follow-up: After prescribing Bijuva, have your staff check in with the patient within a week to confirm they were able to fill the prescription

Final Thoughts

Bijuva availability challenges are manageable with proactive planning and the right resources. By setting expectations at prescribing, directing patients to tools like Medfinder, building reliable pharmacy relationships, and having alternative treatment plans ready, your practice can help patients access the menopausal hormone therapy they need without unnecessary delays.

For additional provider resources, see our companion briefing on what prescribers need to know about the Bijuva shortage in 2026 and our guide on helping patients save money on Bijuva.